| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -28,187 | -20,739 |
| Depreciation and amortization | 280 | 200 |
| Stock-based compensation | 4,134 | 2,601 |
| Decrease in the carrying amount of right-of-use-assets | 1,994 | 1,478 |
| Loss (gain) on sale of property and equipment | -51 | 0 |
| Amortization of premium/discount on purchased securities | -182 | - |
| Amortization of debt issuance costs | 28 | 18 |
| Accretion of final payment on term loans | 98 | 65 |
| Account receivable | -558 | -413 |
| Prepaid expenses and other current assets | 2,309 | 1,545 |
| Deposits | 470 | 458 |
| Foreign withholding tax receivable | 1,899 | 1,899 |
| Other payable | 190 | 189 |
| Other assets | - | 184 |
| Accounts payable | -476 | 804 |
| Accrued expenses | -1,038 | -1,390 |
| Research and development contract liability | 7,731 | 9,494 |
| Operating lease liability | -2,054 | -1,550 |
| Net cash used in operating activities | -20,611 | -11,587 |
| Purchases of property and equipment | 177 | 177 |
| Cash received from the sale of property and equipment | 20 | - |
| Purchases of marketable securities | 16,288 | - |
| Redemption of marketable securities | -9,500 | - |
| Net cash (used in) provided by investing activities | -6,945 | -177 |
| Proceeds from atm offering, net of sales agent commissions and fees | 1,753 | 752 |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of transaction costs | 18,046 | 18,046 |
| Repayment of term loans | -3,000 | -2,000 |
| Net cash provided by financing activities | 16,799 | 16,798 |
| Net decrease in cash, cash equivalents, and restricted cash | -10,757 | 5,034 |
| Cash and cash equivalents at beginning of period | 22,611 | - |
| Cash and cash equivalents at end of period | 11,854 | - |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)